Deliveries of Novavax’ COVID-19 vaccine continue around the world and the first doses arrived in Singapore this week. The Singapore Health Sciences Authority (HSA) previously granted interim authorization for Nuvaxovid™ (NVX-CoV2373) COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. Nuvaxovid was the first protein-based vaccine authorized for use in Singapore.
For more information on Nuvaxovid, including the Summary of Product Characteristics, Prescribing Information and Important Safety Information, adverse event reporting instructions, or to request additional information, please visit the Novavax global authorization website.
NVX-CoV2373 has not yet been authorized for use in the U.S. and the trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.